DKSH Business Unit Healthcare, a Strategic Healthcare Solutions Partner and leading provider of Market Expansion Services for pharmaceutical, over-the-counter (OTC), consumer health and medical device companies, enters a partnership with Kyowa Kirin Co., a Japan-based global specialty pharmaceutical company, in line with Kyowa Kirin’s announced plans to transform its business in Asia-Pacific.

The scope of the partnership covers a promotion and distribution agreement for commercial rights of Kyowa Kirin’s established medicines portfolio in South Korea, Taiwan, Singapore, Thailand, Malaysia, and Hong Kong & Macau as well as global products -- Crysvita in Singapore, Thailand, Malaysia, and Hong Kong & Macau, and Poteligeo in Singapore.

With DKSH’s deep expertise in nephrology, robust distribution networks, and strong commercial capabilities this collaboration reinforces a significant step forward in continuing patient care and accessibility in the region.

“We are very confident about this new journey with DKSH”, stated Abdul Mullick, Ph.D., Chief International Business Officer (CIBO), Kyowa Kirin. “Given DKSH’s proven healthcare expertise and commercial strength across Southeast Asia and North Asia, we are convinced we have chosen the right business partner to continue serving our patients, taking care of our employees and making people smile.”

Bijay Singh, Global Head Business Unit Healthcare, Member of the Executive Committee, DKSH, added: “We are thrilled to embark on this brand new partnership with Kyowa Kirin, especially as they chose DKSH as a regional partner across six markets. This collaboration reflects DKSH’s commitment to driving growth for our clients while at the same time pursuing our mission of providing better healthcare to all patients in our markets. By combining our expertise and resources with Kyowa Kirin’s excellent brands, we are confident we can provide a more cost-effective yet high quality commercial access solution that provides outstanding patient outcomes and customer service.”